Patents by Inventor Chao-Wei Hwang
Chao-Wei Hwang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10987501Abstract: Certain embodiments according to the present invention provide sleeve devices suitable for a wide range of therapeutic uses. In accordance with certain embodiments, the therapeutic sleeve device includes a nanofiber fabric assembly, which defines a plurality of pores, and at least one layer of cells embedded in the nanofiber fabric assembly.Type: GrantFiled: December 27, 2019Date of Patent: April 27, 2021Assignee: The Johns Hopkins UniversityInventors: Chao-Wei Hwang, Zhiyong Xia, Virginia E. Bogdan, Jeffrey A. Brinker, Gary Gerstenblith, Peter V. Johnston, Steven P. Schulman, Gordon Tomaselli, Robert G. Weiss
-
Publication number: 20200297474Abstract: The present invention provides an implantable bioreactor comprising cells enclosed within an enclosure, said cells being capable of producing paracrine factors, wherein the enclosure is collapsible or expandable or both or neither, wherein the enclosure is semipermeable such that it provides containment of the cells preventing the egress of the cells while further providing a barrier that shields the cells from immunological attack, and wherein the enclosure is permeable to the entire secretome of the cell including exosomes, nucleic acids and proteins. The implantable bioreactor can have various configurations and can house internally a cell culture matrix than can include hydrogels, microbeads, and nanofiber matrices along with other active agents.Type: ApplicationFiled: October 5, 2018Publication date: September 24, 2020Inventors: Chao-Wei Hwang, Peter Johnston, Gary Gerstenblith, Robert G. Weiss, Gordon Tomaselli, Steven Schulman
-
Patent number: 10772716Abstract: A method for promoting healing of tissue by delivering a bioreactor into a subject is provided. The bioreactor is an enclosed housing with paracrine factor producing cells enclosed within the housing. The housing is impermeable to the paracrine factor producing cells, impermeable to immunological cells outside of the housing, and permeable to paracrine factors produced by the paracrine factor producing cells. The paracrine factors produced by the paracrine factor producing cells are released out of the housing to promote healing of the tissue.Type: GrantFiled: February 21, 2019Date of Patent: September 15, 2020Assignee: The Johns Hopkins UniversityInventors: Gary Gerstenblith, Jason Benkoski, George Coles, Chao-Wei Hwang, Peter Johnston, Gordon Tomaselli, Robert G. Weiss, Steven P. Schulman, Jeffrey A. Brinker
-
Patent number: 10729337Abstract: The present application relates to systems and methods for non-invasively determining at least one of left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) in a subject's heart, comprising: receiving, by a computer, a plurality of signals from a plurality of non-invasive sensors that measure a plurality of physiological effects that are correlated with functioning of said subject's heart, said plurality of physiological effects including at least one signal correlated with left ventricular blood pressure and at least one signal correlated with timing of heartbeat cycles of said subject's heart; training a machine learning model on said computer using said plurality of signals for periods of time in which said plurality of signals were being generated during a heart failure event of said subject's heart; determining said LVEDP or PCWP using said machine learning model at a time subsequent to said training and subsequent to said heart failure event.Type: GrantFiled: May 5, 2016Date of Patent: August 4, 2020Assignees: The Johns Hopkins University, Boston Scientific Scimed Inc.Inventors: Qian Liu, Nichaluk Leartprapun, Jackline Wanjala, Soumyadipta Acharya, Andrew Bicek, Viachaslau Barodka, Umang Anand, Majd Alghatrif, David Kass, B. Westbrook Bernier, Chao-Wei Hwang, Peter Johnston, Trent Langston
-
Publication number: 20200147358Abstract: Certain embodiments according to the present invention provide sleeve devices suitable for a wide range of therapeutic uses. In accordance with certain embodiments, the therapeutic sleeve device includes a nanofiber fabric assembly, which defines a plurality of pores, and at least one layer of cells embedded in the nanofiber fabric assembly.Type: ApplicationFiled: December 27, 2019Publication date: May 14, 2020Inventors: Chao-Wei Hwang, Zhiyong Xia, Virginia E. Bogdan, Jeffrey A. Brinker, Gary Gerstenblith, Peter V. Johnston, Steven P. Schulman, Gordon Tomaselli, Robert G. Weiss
-
Patent number: 10561830Abstract: Certain embodiments according to the present invention provide sleeve devices suitable for a wide range of therapeutic uses. In accordance with certain embodiments, the therapeutic sleeve device includes a nanofiber fabric assembly, which defines a plurality of pores, and at least one layer of cells embedded in the nanofiber fabric assembly.Type: GrantFiled: October 7, 2014Date of Patent: February 18, 2020Assignee: The Johns Hopkins UniversityInventors: Chao-Wei Hwang, Zhiyong Xia, Virginia E. Bogdan, Jeffrey A. Brinker, Gary Gerstenblith, Peter V. Johnston, Steven P. Schulman, Gordon Tomaselli, Robert G. Weiss
-
Publication number: 20190314416Abstract: A method for promoting healing of tissue by delivering a bioreactor into a subject is provided. The bioreactor is an enclosed housing with paracrine factor producing cells enclosed within the housing. The housing is impermeable to the paracrine factor producing cells, impermeable to immunological cells outside of the housing, and permeable to paracrine factors produced by the paracrine factor producing cells. The paracrine factors produced by the paracrine factor producing cells are released out of the housing to promote healing of the tissue.Type: ApplicationFiled: February 21, 2019Publication date: October 17, 2019Inventors: Gary Gerstenblith, Jason Benkoski, George Coles, Chao-Wei Hwang, Peter Johnston, Gordon Tomaselli, Robert G. Weiss, Steven P. Schulman
-
Patent number: 10376682Abstract: Implantable pressure-actuated systems to deliver a drug and/or other substance in response to a pressure difference between a system cavity and an exterior environment, and methods of fabrication and use. A pressure-rupturable membrane diaphragm may be tuned to rupture at a desired rupture threshold, rupture site, with a desired rupture pattern, and/or within a desired rupture time. Tuning may include material selection, thickness control, surface patterning, substrate support patterning. The cavity may be pressurized above or evacuated below the rupture threshold, and a diaphragm-protective layer may be provided to prevent premature rupture in an ambient environment and to dissipate within an implant environment. A drug delivery system may be implemented within a stent to release a substance upon a decrease in blood pressure. The cavity may include a thrombolytic drug to or other substance to treat a blood clot.Type: GrantFiled: October 11, 2016Date of Patent: August 13, 2019Assignee: The Johns Hopkins UniversityInventors: Chao-Wei Hwang, Hala J. Tomey, Jon R. Resar, Robert C. Matteson, III, George L. Coles, Jr., Jason J. Benkoski, Morgana M. Trexler
-
Publication number: 20180160917Abstract: The present application relates to systems and methods for non-invasively determining at least one of left ventricular end diastolic pressure (LVEDP) or pulmonary capillary wedge pressure (PCWP) in a subject's heart, comprising: receiving, by a computer, a plurality of signals from a plurality of non-invasive sensors that measure a plurality of physiological effects that are correlated with functioning of said subject's heart, said plurality of physiological effects including at least one signal correlated with left ventricular blood pressure and at least one signal correlated with timing of heartbeat cycles of said subject's heart; training a machine learning model on said computer using said plurality of signals for periods of time in which said plurality of signals were being generated during a heart failure event of said subject's heart; determining said LVEDP or PCWP using said machine learning model at a time subsequent to said training and subsequent to said heart failure event.Type: ApplicationFiled: May 5, 2016Publication date: June 14, 2018Applicants: The Johns Hopkins University, Boston Scientific Scimed Inc.Inventors: Qian Liu, Nichaluk Leartprapun, Jackline Wanjala, Soumyadipta Acharya, Andrew Bicek, Viachaslau Barodka, Umang Anand, Majd Alghatrif, David Kass, B. Westbrook Bernier, Chao-Wei Hwang, Peter Johnston, Trent Langston
-
Publication number: 20170245976Abstract: An implantable bioreactor containing a barrier which is designed to allow the release of cell-derived biomolecules, but restricts the entry of immunologic and other cells, or the egress of the cells contained within the bioreactor. Two broad classes of implantable bioreactors are envisioned, encompassing devices for both systemic delivery of the bio-products and local delivery at the target tissue. Bioreactors of both classes can be implanted via surgery, through percutaneous techniques, or other techniques which effect implantation.Type: ApplicationFiled: March 23, 2017Publication date: August 31, 2017Inventors: Gary Gerstenblith, Jason Benkoski, Jeffrey Brinker, George Coles, Chao-Wei Hwang, Peter Johnston, Gordon Tomaselli, Robert G. Weiss, Steven P. Schulman
-
Publication number: 20170028181Abstract: Implantable pressure-actuated systems to deliver a drug and/or other substance in response to a pressure difference between a system cavity and an exterior environment, and methods of fabrication and use. A pressure-rupturable membrane diaphragm may be tuned to rupture at a desired rupture threshold, rupture site, with a desired rupture pattern, and/or within a desired rupture time. Tuning may include material selection, thickness control, surface patterning, substrate support patterning. The cavity may be pressurized above or evacuated below the rupture threshold, and a diaphragm-protective layer may be provided to prevent premature rupture in an ambient environment and to dissipate within an implant environment. A drug delivery system may be implemented within a stent to release a substance upon a decrease in blood pressure. The cavity may include a thrombolytic drug to or other substance to treat a blood clot.Type: ApplicationFiled: October 11, 2016Publication date: February 2, 2017Inventors: Chao-Wei Hwang, Hala J. Tomey, Jon R. Resar, Robert C. Matteson, III, George L. Coles, JR., Jason J. Benkoski, Morgana M. Trexler
-
Patent number: 9504586Abstract: Implantable pressure-actuated systems to deliver a drug and/or other substance in response to a pressure difference between a system cavity and an exterior environment, and methods of fabrication and use. A pressure-rupturable membrane diaphragm may be tuned to rupture at a desired rupture threshold, rupture site, with a desired rupture pattern, and/or within a desired rupture time. Tuning may include material selection, thickness control, surface patterning, substrate support patterning. The cavity may be pressurized above or evacuated below the rupture threshold, and a diaphragm-protective layer may be provided to prevent premature rupture in an ambient environment and to dissipate within an implant environment. A drug delivery system may be implemented within a stent to release a substance upon a decrease in blood pressure. The cavity may include a thrombolytic drug to or other substance to treat a blood clot.Type: GrantFiled: February 13, 2014Date of Patent: November 29, 2016Assignee: The Johns Hopkins UniversityInventors: Chao-Wei Hwang, Hala J. Tomey, Jon R. Resar, Robert C. Matteson, III, George L. Coles, Jr., Jason J. Benkoski, Morgana M. Trexler
-
Publication number: 20160235956Abstract: Certain embodiments according to the present invention provide sleeve devices suitable for a wide range of therapeutic uses. In accordance with certain embodiments, the therapeutic sleeve device includes a nanofiber fabric assembly, which defines a plurality of pores, and at least one layer of cells embedded in the nanofiber fabric assembly.Type: ApplicationFiled: October 7, 2014Publication date: August 18, 2016Inventors: Chao-Wei Hwang, Zhiyong Xia, Virginia E. Bogdan, Jeffrey A. Brinker, Gary Gerstenblith, Peter V. Johnston, Steven P. Schulman, Gordon Tomaselli, Robert G. Weiss
-
Publication number: 20150335788Abstract: A therapeutic patch includes at least one layer of a nanofiber fabric and at least one of a plurality of stem cells or a plurality of stem cell-derived paracrine factors embedded in the nanofiber fabric. The therapeutic patch is produced such that the nanofiber fabric is formed of a nanofiber web.Type: ApplicationFiled: March 5, 2015Publication date: November 26, 2015Inventors: Zhiyong Xia, Chao-Wei Hwang, Xiomara Calderon-Colon, Virginia E. Bogdan, Peter V. Johnston
-
Publication number: 20150217030Abstract: Certain embodiments according to the present invention provide a method for forming medical devices conformally coated with a hydrogel having a wide variety of therapeutic uses. In one aspect, certain embodiments of the invention provide a method for forming a hydrogel-coated medical device comprising immersing a medical device in a polymer solution to form an adhesive layer on an outer surface of the medical device and contacting the medical device with a hydrogel precursor solution having a pH of less than 7 to react the adhesive layer with the hydrogel precursor solution and form a conformal hydrogel coating.Type: ApplicationFiled: February 5, 2015Publication date: August 6, 2015Inventors: Jason J. Benkoski, Peter V. Johnston, Chao-Wei Hwang, Gary Gerstenblith, Robert G. Weiss, Gordon Tomaselli, Steven P. Schulman, Jeffrey A. Brinker
-
Publication number: 20150209299Abstract: A medical device includes a plurality of drug-eluting nanofibers directly or indirectly located over an outer surface of the medical device, or utilized independently as a tissue engineering scaffold. The plurality of drug-eluting nanofibers include one or more therapeutic agents.Type: ApplicationFiled: January 28, 2015Publication date: July 30, 2015Inventors: Zhiyong Xia, Chao-Wei Hwang
-
Publication number: 20140188213Abstract: Implantable pressure-actuated systems to deliver a drug and/or other substance in response to a pressure difference between a system cavity and an exterior environment, and methods of fabrication and use. A pressure-rupturable membrane diaphragm may be tuned to rupture at a desired rupture threshold, rupture site, with a desired rupture pattern, and/or within a desired rupture time. Tuning may include material selection, thickness control, surface patterning, substrate support patterning. The cavity may be pressurized above or evacuated below the rupture threshold, and a diaphragm-protective layer may be provided to prevent premature rupture in an ambient environment and to dissipate within an implant environment. A drug delivery system may be implemented within a stent to release a substance upon a decrease in blood pressure. The cavity may include a thrombolytic drug to or other substance to treat a blood clot.Type: ApplicationFiled: February 13, 2014Publication date: July 3, 2014Applicant: Johns Hopkins UniversityInventors: Chao-Wei Hwang, Hala J. Tomey, Jon R. Rosar, Robert C. Matteson, George L/ Coles, Jason J. Benkoski, Morgana M. Trexler
-
Patent number: 8696740Abstract: Implantable pressure-actuated systems to deliver a drug and/or other substance in response to a pressure difference between a system cavity and an exterior environment, and methods of fabrication and use. A pressure-rupturable membrane diaphragm may be tuned to rupture at a desired rupture threshold, rupture site, with a desired rupture pattern, and/or within a desired rupture time. Tuning may include material selection, thickness control, surface patterning, substrate support patterning. The cavity may be pressurized above or evacuated below the rupture threshold, and a diaphragm-protective layer may be provided to prevent premature rupture in an ambient environment and to dissipate within an implant environment. A drug delivery system may be implemented within a stent to release a substance upon a decrease in blood pressure. The cavity may include a thrombolytic drug to or other substance to treat a blood clot.Type: GrantFiled: January 5, 2011Date of Patent: April 15, 2014Assignee: The Johns Hopkins UniversityInventors: Chao-Wei Hwang, Hala J. Tomey, Jon R. Rosar, Robert C. Matteson, III, George L. Coles, Jr., Jason J. Benkoski, Morgana M. Trexler
-
Publication number: 20120083767Abstract: An implantable bioreactor containing a barrier which is designed to allow the release of cell-derived biomolecules, but restricts the entry of immunologic and other cells, or the egress of the cells contained within the bioreactor. Two broad classes of implantable bioreactors are envisioned, encompassing devices for both systemic delivery of the bio-products and local delivery at the target tissue. Bioreactors of both classes can be implanted via surgery, through percutaneous techniques, or other techniques which effect implantation.Type: ApplicationFiled: October 3, 2011Publication date: April 5, 2012Applicant: The Johns Hopkins UniversityInventors: Gary Gerstenblith, Jason Benkoski, Jeffrey Brinker, George Coles, Chao-Wei Hwang, Peter Johnston, Gordon Tomaselli, Robert G. Weiss, Steven P. Schulman
-
Publication number: 20120010698Abstract: Implantable pressure-actuated systems to deliver a drug and/or other substance in response to a pressure difference between a system cavity and an exterior environment, and methods of fabrication and use. A pressure-rupturable membrane diaphragm may be tuned to rupture at a desired rupture threshold, rupture site, with a desired rupture pattern, and/or within a desired rupture time. Tuning may include material selection, thickness control, surface patterning, substrate support patterning. The cavity may be pressurized above or evacuated below the rupture threshold, and a diaphragm-protective layer may be provided to prevent premature rupture in an ambient environment and to dissipate within an implant environment. A drug delivery system may be implemented within a stent to release a substance upon a decrease in blood pressure. The cavity may include a thrombolytic drug to or other substance to treat a blood clot.Type: ApplicationFiled: January 5, 2011Publication date: January 12, 2012Inventors: Chao-Wei Hwang, Hala J. Tomey, Jon R. Rosar, Robert C. Matteson, III, George L. Coles, JR., Jason J. Benkoski, Morgana M. Trexler